Cleanascite™ for reducing matrix effects of samples during bioanalysis .

Cleanascite™ from Biotech Support Group is cited in U.S patent application 20110263040 titled, “Devices and Methods For Reducing Matrix Effects”. Cleanascite™ is used for selectively removing lipids, cell debris, lipoproteins, floating fats, impurities  for pretreatment of samples prior to purification. According to U.S. Patent. No. 5,885,921 to Krupey, Cleanascite™ is an ideal lipid adsorbent and clarification agent for the removal of lipids in samples from cohn paste, transgenic milk, egg yolk and biological samples.

Cleanascite™ allows scientists to perform the most accurate, precise selective, sensitive and robust bioanalytical method on samples. Published research on Cleanascite showcases unique sample preparation applications in lifescience research. Examples of published articles are:

• Thrombin-inhibiting perfluorocarbon nanoparticles provide a novel strategy for treatment and magnetic resonance imaging of acute thrombosis Journal of Thrombosis and Haemostasis J. Myerson, L. He et al 2011. Red blood cells release factors with growth and survival bioactivities for normal and leukemic T cells Immunology and Cell Biology (2011) 89, 111–121
• Dujuan Li, Jianping Wang, Ronghui Wang, Yanbin Li, Daad Abi-Ghanem, Luc Berghman, Billy Hargis, Huaguang Lu, A nanobeads amplified QCM immunosensor for the detection of avian influenza virus H5N1, Biosensors and Bioelectronics, Volume 26, Issue 10, 15 June 2011, Pages 4146-4154
• Analysis conditions for proteomic profiling of mammalian tissue and cell extracts with antibody microarrays. Alhamdani MS, Schröder C, Hoheisel JD, Division of Functional Genome Analysis, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany. Proteomics. 2010 Sep;10(17):3203-7

Bioanalysis is analyzing (using LC-MS or HPLC) drug/metabolites/biomarkers (qualitative/ quantitative) in biological samples such as plasma, serum, whole blood, urine, saliva, tissues, etc. The matrix effect is the ion-suppression and/or enhancement observed in electrospray ionization (ESI) and atmospheric pressure chemical ionization (APCI)during LC-MS use. Such interference coming from biological matrix is reduced with Cleanascite sample preparation reagent. Pretreatment of samples reduces interferences of contaminants and increases accuracy of analytes during bioanalytical testing and quantitation methods such as liquid chromatography-mass spectrometry/mass spectrometry.  For example, matrix effects or ion suppression caused by phospholipids (phosphatidylcholines) in mass spectrometry results in low recovery and high variation of results.
Properties of Cleanascite™ include:

• A high binding capacity for lipids with minimal cross-reactivity with proteins
• Effectively replaces chlorinated/fluorinated hydrocarbons (eg. freon) and it is environmentally friendly.
• Does not bind to DNA, RNA, enzymes and proteins
• Leaves glycoproteins, antibodies, nucleic acids, hemoglobin, proteoglycans, nucleic acids, serum components(such as hormones, nutrients, globulins, clotting factors, transport proteins) alone
• Extends the life of membrane and chromatographic columns.
• Enrichment of delipidated tissue samples
• Ideal for delipidation treatments for downstream processing of large-scale therapeutic proteins, enzymes and monclonal antibodies.
• Cleanascite™ reduces the risk of matrix effects in samples analyzed with LC/MS-MS for drug metabolism studies preventing  analytical errors from phospholipids, acylglycerols and cholesterols & glycerophosphocholines on electrospray ionization efficiencies for target analytes.

Cleanascite™ complements removal of phospholipids from bioanalytical samples including liquid/liquid extraction  and solid phase extraction, acetonitrile protein precipitation, strong cation exchange columns, phospholipotropic multivalent cation coupled to a support. Utimately, proper sample preparation allows for precise  results of toxicokinetic, pharmacokinetic and bioequivalence studies which are essential for making important decisions  in supporting critical safety and efficacy data of a medicinal drug substance or product.
For more information visit Biotech Support Group:
http://www.biotechsupportgroup.com/node/73

References for Cleanascite™:

• Thrombin-inhibiting perfluorocarbon nanoparticles provide a novel strategy for treatment and magnetic resonance imaging of acute thrombosis Journal of Thrombosis and Haemostasis J. Myerson, L. He et al 2011. Red blood cells release factors with growth and survival bioactivities for normal and leukemic T cells Immunology and Cell Biology (2011) 89, 111–121
• Dujuan Li, Jianping Wang, Ronghui Wang, Yanbin Li, Daad Abi-Ghanem, Luc Berghman, Billy Hargis, Huaguang Lu, A nanobeads amplified QCM immunosensor for the detection of avian influenza virus H5N1, Biosensors and Bioelectronics, Volume 26, Issue 10, 15 June 2011, Pages 4146-4154
• Analysis conditions for proteomic profiling of mammalian tissue and cell extracts with antibody microarrays. Alhamdani MS, Schröder C, Hoheisel JD, Division of Functional Genome Analysis, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany. Proteomics. 2010 Sep;10(17):3203-7

Suggested References for Cleanascite™:

• Baltussen E, Cramers CA and Sandra PJF. Sample preparation—a review. Analytical and Bioanalytical Chemistry 2002; 373(1–2): 3–22
• Berrueta LA, Gallo B and Vicente F. A review of solid phase extraction: basic principles and new developments. Chromatographia 1995; 40(7–8): 474–483
• Biddlecombe RA and Pleasance S. Automated protein precipitation by filtration in the 96-well format. Journal of Chromatography B 1999; 734(2): 257–265
• Fu X, Liao Y and Liu H. Sample preparation for pharmaceutical analysis. Analytical and Bioanalytical Chemistry 2005; 381(1): 1618–2642